ArrowMark Colorado Holdings’s Adaptive Biotechnologies ADPT Stock Holding History

ArrowMark Colorado Holdings’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-104,224	Closed	-$5.04M	–	335
2020 Q2	$5.04M	Sell	104,224 -10,062	-9%	-$367K	0.05%	191
2020 Q1	$3.17M	Sell	114,286 -2,327	-2%	-$64.9K	0.04%	194
2019 Q4	$3.49M	Sell	116,613 -24,366	-17%	-$700K	0.03%	223
2019 Q3	$4.36M	Sell	140,979 -9,021	-6%	-$368K	0.04%	198
2019 Q2	$7.25M	Buy	+150,000	New	+$6.64M	0.07%	184

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

SIG

Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return

ArrowMark Colorado Holdings's ADPT Position: Q3 2020 in Review

ArrowMark Colorado Holdings sold out of Adaptive Biotechnologies (ADPT) in Q3 2020, closing a stake of 104,224 shares — an estimated $5.04M sold.

ArrowMark Colorado Holdings first reported a position in ADPT in Q2 2019 and held it in 5 quarters. The position peaked at $7.25M in Q2 2019. 206 funds tracked by Wall St. Rank hold ADPT as of Q3 2020.

ArrowMark Colorado Holdings reported no remaining Adaptive Biotechnologies position as of Q3 2020 after selling out during the quarter.
ArrowMark Colorado Holdings sold 104,224 Adaptive Biotechnologies shares in Q3 2020, an estimated $5.04M.
ArrowMark Colorado Holdings first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 5 quarters.
ArrowMark Colorado Holdings's Adaptive Biotechnologies position peaked at $7.25M in Q2 2019.
206 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2020.

Based on ArrowMark Colorado Holdings's 13F filing for Q3 2020, filed 16 Nov 2020.